Aurolab Foundation Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aurolab Foundation Pharmaceutical Export Portfolio Dataset — 2 Products, $184.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aurolab Foundation — Pharmaceutical Exporter Profile (2026) | 2 Products, $184.4K Trade | TransData Nexus

Aurolab Foundation

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $184.4K Total Trade · DGFT Verified

Aurolab Foundation is an Indian pharmaceutical exporter with a total trade value of $184.4K across 2 products in 2 therapeutic categories. Based on 55 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Chondroitin ($182.3K), Gatifloxacin ($2.2K), .

Aurolab Foundation — Export Portfolio & Destination Treemap

Aurolab Foundation pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aurolab Foundation? — Company Overview & Market Position

Aurolab Foundation is a private not-for-profit organization established on June 29, 2023, in Madurai North, Tamil Nadu, India. Operating under the Corporate Identification Number (CIN) U86909TN2023NPL161532, the foundation is registered with the Registrar of Companies, Chennai. The registered office is located at SBI Building, No.1 Sivagangai Main Road, Veerapanjan, Madurai North, Tamil Nadu, 625020.

The foundation is primarily engaged in human health activities, focusing on eye care and ophthalmology clinics. As a not-for-profit entity, it operates with the mission to provide accessible and affordable eye care solutions. The ownership structure comprises promoters holding 92.83%, the public at 4.10%, and others at 3.07%.

What Does Aurolab Foundation Export? — Product Portfolio Analysis

Top Products by Export Value

1Chondroitin$182.3K 2Gatifloxacin$2.2K

Product Portfolio — Top 2 by Export Value

Aurolab Foundation exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Chondroitin	Nutritional Supplements	$182.3K	44	3.6%	7
2	Gatifloxacin	Advanced Antibiotics	$2.2K	11	0.3%	9

Aurolab Foundation exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $184.4K. The top category is Nutritional Supplements (98.8% of portfolio), followed by Advanced Antibiotics (1.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aurolab Foundation — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aurolab Foundation's manufacturing facilities are situated in Madurai, Tamil Nadu, India. The company specializes in the production of ophthalmic pharmaceuticals, including tablets, capsules, syrups, and injections. While specific details regarding plant capacities are not publicly disclosed, the foundation is known for its commitment to quality and compliance with global standards.

3Key Leadership

The leadership team of Aurolab Foundation includes:

Aravind Srinivasan
Thulasiraj Duraisamy
Ramasamy Kim
Namperumalsamy Venkatesh Prajna
Ravilla Duraisami Sriram

These directors are responsible for guiding the foundation's strategic direction and ensuring the effective delivery of its mission in the field of eye care.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aurolab Foundation Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

As of March 2026, Aurolab Foundation has not publicly disclosed specific regulatory approvals or market access statuses in the United States, European Union, United Kingdom, Australia, or Japan. The foundation's focus appears to be on the Indian market, with a strong emphasis on providing affordable eye care solutions domestically. Given its not-for-profit status, the foundation's international expansion may be limited, and it is advisable to consult directly with the organization for the most current information regarding its regulatory standing in these regions.

2Emerging Markets

Aurolab Foundation's primary operations are centered in India, with a significant impact on the domestic eye care sector. While the foundation's not-for-profit model suggests a focus on local initiatives, there is no publicly available information indicating its penetration into African, Latin American, or Southeast Asian markets. The foundation's mission to provide accessible eye care solutions may align with global health initiatives, but specific details regarding its presence in these emerging markets are not disclosed.

3Geographic Strategy

Aurolab Foundation — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As a not-for-profit organization based in India, Aurolab Foundation's products are primarily intended for the Indian market. There is no publicly available information indicating that the foundation has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA) or holds approved Abbreviated New Drug Applications (ANDAs) or Drug Master Files (DMFs) with the FDA. The foundation's focus on domestic operations suggests that its products are not marketed in the United States.

2WHO & EU GMP

Aurolab Foundation's commitment to quality is evident in its adherence to global standards. The foundation's products are manufactured in compliance with Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO) and the European Union (EU). This adherence ensures that the foundation's ophthalmic pharmaceuticals meet international quality standards, reflecting its dedication to providing safe and effective eye care solutions.

3CDSCO & Indian Regulatory

Aurolab Foundation — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Indian ophthalmic pharmaceutical sector, Aurolab Foundation faces competition from both domestic and international companies. Key competitors include Alcon India, Novartis India, and Bausch & Lomb India, which offer a range of ophthalmic products. Aurolab Foundation differentiates itself through its not-for-profit model, focusing on providing affordable eye care solutions to underserved populations. While specific market share data is not publicly available, the foundation's unique approach positions it as a significant player in the domestic market.

2Key Differentiators

Aurolab Foundation's primary differentiator is its not-for-profit status, which enables it to offer high-quality ophthalmic pharmaceuticals at affordable prices. This model allows the foundation to reinvest any surplus into expanding its services and outreach programs, thereby increasing access to eye care for underserved communities. Additionally, the foundation's adherence to WHO and EU GMP standards ensures that its products meet international quality benchmarks, further enhancing its reputation in the market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Aurolab Foundation as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aurolab Foundation's track record as a supplier is characterized by its commitment to quality and affordability. The foundation's products are manufactured in compliance with WHO and EU GMP standards, ensuring consistency and reliability. Its not-for-profit model allows for reinvestment into services and outreach programs, demonstrating a sustainable approach to operations. While specific export volumes and consistency metrics are not publicly disclosed, the foundation's widespread recognition and trust among eye care professionals indicate a strong and reliable supply chain.

2Certifications to Verify

Importers seeking to verify Aurolab Foundation's certifications should confirm the following:

WHO-GMP Certification: This certification ensures that the manufacturing processes meet the World Health Organization's standards for pharmaceutical products. Verification can be obtained by contacting the foundation directly or consulting the WHO's official database.

EU GMP Certification: This certification indicates compliance with the European Union's Good Manufacturing Practices. Importers can verify this certification by reaching out to the foundation or checking the EU's official records.

Frequently Asked Questions — Aurolab Foundation

How many pharmaceutical products does Aurolab Foundation export from India?

Aurolab Foundation exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Chondroitin ($182.3K), Gatifloxacin ($2.2K). Total export value is $184.4K.

What is Aurolab Foundation's total pharmaceutical export value?

Aurolab Foundation's total pharmaceutical export value is $184.4K, based on 55 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aurolab Foundation cover?

Aurolab Foundation exports across 2 therapeutic categories. The largest are Nutritional Supplements (98.8%, 1 products), Advanced Antibiotics (1.2%, 1 products).

Get Full Aurolab Foundation Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.